The 2026 American Academy of Dermatology (AAD) Annual Meeting

Treatment with deuruxolitinib, an oral Janus kinase 1/2 inhibitor, resulted in significant hair regrowth on the scalp for 24 weeks among patients with severe alopecia areata (AA), according to the two phase III THRIVE-AA1 and -AA2 trials presented at AAD 2026.

The use of cannabis appears to result in a lower incidence of basal cell carcinoma (BCC) over 10 years, but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), suggests a recent study presented at AAD 2026.

Patients with psoriasis who are treated with methotrexate (MTX) show a reduced incidence of metabolic syndrome and better cardiometabolic profiles, according to a study presented at AAD 2026.

A study presented at AAD 2026 adds to growing evidence showing that almonds can combat acne.

Data from two phase III ICONIC-ADVANCE studies presented at AAD 2026 reinforce the potential of the investigational first-in-class targeted oral peptide icotrokinra for the treatment of plaque psoriasis (PsO).